Gerilimzumab - argenx/Genor Biopharma
Alternative Names: Anti-IL6-monoclonal-antibody-Genor-Biopharma; Anti-interleukin-6-monoclonal-antibody-Genor-Biopharma; ARGX 109; GB 224; RYI 008Latest Information Update: 01 Jul 2024
At a glance
- Originator arGEN-X
- Developer argenx; Bird Rock Bio; Genor Biopharma
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Interleukin 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
- Discontinued Autoimmune disorders; Cancer; Rheumatoid arthritis